TP53异常(突变或/和缺失)是慢性淋巴细胞白血病(CLL)的重要预后不良因素,以往甚至称为超高危CLL,这类患者占初治CLL比例约8-10%,复发难治超过30%,通常临床疾病进展较快,生存期短,预后差。目前已经报导显示BTKi对于具有TP53异常CLL疗效由...
Genomic aberrations and gene mutations are among the strongest prognostic factors in CLL. In particular, patients with mutated TP53 (TP53mut) and/or deleted chromosome 17p (del17p) have a worse response to therapy and significantly shorter progression-free survival (PFS) and overall survival (OS...
8. Komrokji RS, Sallman DA, Al Ali N, et al. Outcome of myelodysplastic syndrome patients with TP53 mutation treated with hypomethylating agents. Blood. 2017;130:1687. 9. Nannya Y, Takeda J, Sato S, et al. Molecular signatures that predict response to 阿扎胞苷citidine treatment for my...
Empty CellWhole cohortTP53 wtHigh-burden TP53 mutation (≥10% VAF)Low-burden TP53 mutation (1-10% VAF)Low-burden TP53 mutation (<1% VAF)P* No. of patients 511 370 (72) 59 (12) 29 (6) 53 (10) — Age at first-line treatment, median y (range) 67.31 (35.0-94.0) 66.8 (37.43-...
目的分析传统免疫化疗(CIT)时代,TP53基因异常[TP53缺失和(或)突变]慢性淋巴细胞白血病(CLL)患者一线CIT疗效及生存情况。 方法收集2003年1月至2017年8月在江苏省人民医院血液科诊断的118例TP53异常CLL患者基线资料[性别、年龄、分期、B症状(发热、盗汗、体重减低)、β 2微球蛋白(β 2-MG)、免疫球蛋白重链可变区(...
在慢性淋巴细胞白血病(chronic lymphocytic leukemia, CLL)中,TP53基因分析是疾病预后评估的重要部分,目前成为常规临床检测,主要针对TP53基因突变和TP53缺失(17p-)两个方面进行。二代测序检测TP53基因突变是目前有效的技术手段,其中靶向深度测序还可检测低丰度的突变(...
Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials. Blood. 2020; 136 (...
Specific to Del17p CLL or TP53 mutation in the frontline setting, Farooqui et al. [5] reported on the outcomes of 35 treatment-naïve patients who received ibrutinib. The median age was 62 (range, 33–82) years. The ORR was 97% with 12% attaining CR, 70% PR, and 15% PR with ...
ConclusionTP53 gene mutation is a risk factor affecting OS of MDS patients. KEYWORDS: Myelodysplastic syndromes;TP53 gene mutation;Overall survival time;Next gene sequencing;Meta-analysis Corresponding author: Hu Xiaomei, Email: moc.3612_iemoaixuh FUNDING: National Natural Science Foundation of China...
In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CL